All In MedTech

FDA Clearance Tracker · P170038

CentriMag Circulatory Support System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 6, 2019 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 6, 2019

Approved

Time to decision

742 days

Received Nov 24, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P170038
Device name
CentriMag Circulatory Support System
Applicant
Abbott
Applicant location
Pleasanton, CA
Received
Nov 24, 2017
Decided
Dec 6, 2019
Decision
Approved
Supplements
33 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III
Specialty
Cardiology

Every decision under product code DSQ

FDA's approval statement

As written in FDA's record.

Approval for temporary circulatory support for up to 30 days for one or both sides of the heart to treat postcardiotomy patients who fail to wean from cardiopulmonary bypass, providing a bridge to decision when it is unclear whether the patient's heart will recover or whether the patient will need alternative, longer-term therapy.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code DSQ. The earliest in FDA's data is P900023, decided Nov 20, 1992.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Abbott

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.